Safety & Tolerability
CAPLYTA demonstrated safety in over 1,700 US adult patients1
Most common adverse reactions in 4- to 6-week inpatient trials (morning dosing)1,3*
|CAPLYTA 42 mg (n=406)||Placebo (n=412)|
Incidence of at least 5% of subjects exposed to CAPLYTA and greater than twice the rate of placebo.1
- Somnolence with CAPLYTA was predominantly mild3
- There was no single adverse reaction leading to discontinuation that occurred at a rate of >2% in
In 4- to 6-week trials, patients on CAPLYTA experienced metabolic, EPS, prolactin, and weight changes similar to placebo1,3
Antipsychotic drugs have been reported to cause:
- Hyperglycemia, diabetes, dyslipidemia, and weight gain. Blood glucose, weight, and lipids should be monitored periodically during long-term treatment.
- Tardive dyskinesia (TD), which may increase as the duration of treatment and cumulative dose increases, and can develop after brief treatment periods or after discontinuation. See additional Important Safety Information below.